Tag: Hospital

  • California health workers may face rude awakening with $25 minimum wage law

    California health workers may face rude awakening with $25 minimum wage law

    [ad_1]

    Nearly a half-million health workers who stand to benefit from California’s nation-leading $25 minimum wage law could be in for a rude awakening if hospitals and other health care providers follow through on potential cuts to hours and benefits.

    A medical industry challenge to a new minimum wage ordinance in one Southern California city suggests layoffs and reductions in hours and benefits, including cuts to premium pay and vacation time, could be one result of a state law set to begin phasing in in June. However, some experts are skeptical of that possibility.

    The California Hospital Association brought a partly successful legal challenge to Inglewood’s $25 minimum wage ordinance, which barred employers from taking those sorts of steps to offset their higher costs.

    “Layoffs, reductions in premium pay rates, reductions in non-wage benefits, reductions in hours, and increased charges are consequences of an employer having less money to spend—which will necessarily be the case given the significant increase in spending on wages due to the minimum wage,” the association said in its lawsuit. Additional examples include reducing health coverage and charging for parking or work-related equipment.

    Inglewood voters approved the ordinance in November 2022, nearly a year before California legislators enacted a $25 minimum wage for health workers. Those statewide higher wages are to be phased in starting in June under California’s first-in-the-nation law, but Gov. Gavin Newsom has since said they are too expensive as the state faces a deficit estimated between $38 billion and $73 billion. It’s unclear if lawmakers will agree to a delay or take other steps to reduce the cost.

    U.S. District Judge Dale S. Fischer agreed with the hospital industry in a March 11 tentative ruling when he shot down the portion of Inglewood’s ordinance banning layoffs and clawbacks by employers, while allowing the rest of the ordinance to remain in effect. He gave the sides time to object to his preliminary decision, though none did.

    The California Hospital Association represents more than 400 hospitals and was a key backer of the state’s carefully crafted compromise law, which notably contains none of the employee safeguards included in the Inglewood ordinance.

    Spokesperson Jan Emerson-Shea said the association doesn’t know how providers will react once the state law takes effect. “We don’t have any insights,” she said.

    “The challenge for any health care organization is figuring out how to pay for the higher wages,” said Joanne Spetz, director of the Philip R. Lee Institute for Health Policy Studies at the University of California-San Francisco. “Since labor costs are the largest part of any health care organization’s costs, it’s hard to figure out how to reduce spending without looking at labor costs.”

    Providers can try to increase revenues by bargaining for higher reimbursements from commercial insurers, she said. Public hospitals, nursing homes, and community clinics get most of their money through Medi-Cal, the state’s Medicaid program.

    Providers could reduce the services they offer, pare back charity care, and cut or delay capital investments, Spetz said. In the long term, she expects some combination of spending cuts and revenue increases.

    Both the state law and local ordinance cover far more than doctors and nurses, with a definition of health worker that includes janitors, housekeepers, groundskeepers, security guards, food service workers, laundry workers, and clerical staff.

    The most recent estimate by the Health Care Program at the University of California-Berkeley Labor Center is that as many as 426,000 health workers would make an average of $6,400 extra in the law’s first year, a 19% average pay bump mainly benefiting lower-income workers of color and women. State finance officials project that well over 500,000 workers will benefit.

    Researchers didn’t include layoffs and other potential staffing and benefit reductions when they projected the state law’s costs and benefits, said Laurel Lucia, the program’s director. But she pointed to initial projections by hospitals, doctors, and business and taxpayer groups that the wage hike would cost $8 billion annually, thereby imperiling services and resulting in higher premiums and higher costs for state and local governments.

    “It seems like a contradiction to say this law’s going to cost billions of dollars while at the same time saying it’s going to reduce workers’ total compensation,” said Lucia, who projects a far lower price tag.

    She added that state finance officials had anticipated that Medi-Cal reimbursements would reflect the increased labor costs, while Medicare would eventually at least partially compensate for the higher labor costs.

    Michael Reich, chair of the Center on Wage and Employment Dynamics at UC Berkeley’s Institute for Research on Labor and Employment, and affiliated economist Justin Wiltshire recently argued that California’s new $20 minimum wage law for fast-food workers won’t result in mass layoffs and price increases, as some have predicted.

    Health care is much different than fast food, Reich acknowledged, but he argued for much the same positive result.

    “A higher minimum wage will make it easier and cheaper for hospitals to recruit and retain these workers. The cost savings, and the productivity benefits of more experienced workers, could offset much of the labor cost increase,” Reich said.

    The hospital association filed its lawsuit against Inglewood’s ordinance in July, while it was still opposing early versions of the statewide minimum wage legislation. Among many other provisions, the statewide law put on hold an initiative to cap hospital executives’ salaries in Los Angeles.

    The hospital association’s legal challenge referenced in part layoffs and reduced working hours imposed by Centinela Hospital Medical Center after Inglewood’s ordinance took effect.

    But Centinela said the reduction was entirely unrelated to the ordinance and that all staff were offered alternate positions, which many accepted.

    “Centinela Hospital also has since added many more jobs in new clinical positions above minimum wage scale,” the hospital said in a statement.

    Service Employees International Union-United Healthcare Workers West, the prime backer of both the local ordinance and the statewide law, sued the hospital in April 2023 alleging that it cut workers’ hours to offset the higher minimum wage. The case is still pending.

    The union did not respond to repeated requests for comment.

    In a court filing, however, the union and city of Inglewood said similar employer restrictions in previous minimum wage laws have survived.

    The ordinance “merely sets the backdrop for collective bargaining negotiations,” and does not bar employers from locking out employees or hiring replacement workers during a strike. Employers can still lay off workers or reduce their hours, they said, so long as they don’t do so to fund the higher minimum wage.

    But Fischer agreed with the hospital association that layoffs and reductions in employees’ total compensation packages are “obvious responses by an employer to rising compensation costs.”

    Restricting employers’ options would violate federal labor relations rules, he said.

    “The minimum wage an employer has to pay its employees will invariably affect the total amount of compensation it is able or willing to pay,” he wrote “This will then invariably affect the number of employees it can retain and the number of hours those employees will be scheduled to work.”

    This article was produced by KFF Health News, which publishes California Healthline, an editorially independent service of the California Health Care Foundation. 




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link

  • Study shows potential for universal flu vaccine with broad antibody response

    Study shows potential for universal flu vaccine with broad antibody response

    [ad_1]

    A recent study published in the journal Nature Communications observed antibody breadth and effector functions as important immune correlates that can be used to develop universal influenza vaccines. This vaccine could be effective against all influenza virus strains, even those having pandemic potential.

    Study: Influenza antibody breadth and effector functions are immune correlates from acquisition of pandemic infection of children. Image Credit: Africa Studio / ShutterstockStudy: Influenza antibody breadth and effector functions are immune correlates from acquisition of pandemic infection of children. Image Credit: Africa Studio / Shutterstock

    Background

    Children are particularly vulnerable to influenza viruses that cause seasonal epidemics and sporadic pandemics. Seasonal influenza epidemics not only lead to an upsurge in hospital admissions but also increase mortality rates in older adults with comorbidities. Many studies have shown that seasonal influenza vaccines provide limited protection against influenza viruses that have the potential to cause a pandemic. However, the 2009 H1N1 pandemic (pH1N1) revealed the effectiveness of seasonal vaccines in protecting children and older adults from the infection. This protection could be due to cross-reactive antibody responses. 

    Compared to children, adults possess additional immune correlates, such as T-cell responses and non-neutralizing antibody functions. This is the reason why children require higher concentrations of HAI antibodies for an equivalent amount of immune protection from the infection. To design a next-generation vaccine, it is important to identify immune correlates of protection. In the context of pH1N1 infection, HA-stem-specific antibodies play a crucial role in providing protection, which is mediated by the Fc Receptor (FcR) function. 

    Some antibodies that can cross-react between pandemic, seasonal, and avian influenza viruses could reduce the severity of influenza virus infection. In this context, serum antibodies, particularly IgG, can facilitate effector functions, such as directing immune cells to kill infected cells, engulfing infected cells via antibody-dependent phagocytosis (ADCP), and promoting antibody-dependent cellular cytotoxicity (ADCC). These functions are mediated by Fc gamma receptors (FcγR) 3a and FcγR2a.

    Mechanistically, FcγR 3a and FcγR2a employ macrophages and natural killer (NK) cells to remove viruses-infected cells. Cross-reaction of ADCC antibodies has been associated with targeting conserved antigenic sites of influenza virus hemagglutinin (HA), the Nucleoprotein (NP), and Matrix 1 (M1).

    About the Study

    The current study identified several gaps in research regarding antibody effector functions. For instance, few studies have assessed the vaccine-induced ADCC changes, longitudinal durability of vaccine-induced antibody FcR binding and isotype changes, and the alterations in HA-specific antibody responses with vaccination and infection. The currently performed randomized placebo control trial (RCT) investigated the influenza-specific antibody breadth and function of seasonal (S1) H1N1 vaccination and pH1N1 infection.

    The antibody features, particularly HAI titer, from seasonal vaccination that could have helped in reducing or delaying contraction of pH1N1 were assessed using selected archived samples. These samples were collected from NCT00792051, a randomized placebo-controlled trial and its follow-up study that used school children between 6 and 17 years old. 

    A subset of children who received any influenza vaccination in Year 1 (V1) or not (placebo-V0) was selected for secondary analyses, which helped determine the effectiveness of vaccination against pH1N1 infection.

    Study Findings

    The current study indicated that non-neutralizing antibodies are highly cross-reactive between different influenza strains and subtypes, which could play an important role in reducing the incidence and severity of infection.

    Detecting antibody functions other than HAI is vital to developing next-generation vaccines. This study identified the serological correlates that play an important role in protecting children from pandemic infection. In 2009, when schools were closed for two months, H1N1 transmission was low. However, soon after schools reopened in September 2009, more than 50% of the students were infected within a few months. A very low community uptake of the monovalent pH1N1 vaccine has been documented.

    The half-life of different antibody subclasses alters significantly. The current study observed that seasonal vaccination enhances Fc effector functions of pH1N1 specific NP, HA, and neuraminidase (NA) antibodies. However, their function was short-term as it waned off within one year of vaccination. A greater antibody decline was observed in unvaccinated children.

    Seasonal vaccination did not boost FcR effector functions to other seasonal-specific antibody responses. Unvaccinated, uninfected children also exhibited increased FcR-mediated effector functions of pandemic-specific NA, HA, and NP antibodies. These children displayed a higher antibody level of NK cell function. pH1 antibodies against H3-HA responses were associated with cross-reactive avian H5-specific IgG, FcγR2a, and FcγR3a responses. This finding implies that cross-reactive responses are less focused and are not trained by seasonal virus exposure of other groups. 

    Considering the experimental results, vaccination and prior infection are not associated with the lack of infection in unvaccinated, uninfected children or susceptibility of V1S1 children. More research is required to understand the host factors leading to these outcomes.

    Results also indicated that group 2 H3 HA-specific IgG3 antibodies are negative predictors of infection. However, seasonal H1 and pH1-IgG3 antibodies before infection were positively associated and, therefore, protected against infection.

    Conclusions

    This study shows how universal influenza vaccines, effective against seasonal to pandemic viruses, can be developed. Antibody breadth and FcR effector functions are two important immune correlates that could be exploited to develop this vaccine.

    Journal reference:

    • Jia, J. Z. et al. (2024) Influenza antibody breadth and effector functions are immune correlates from acquisition of pandemic infection of children. Nature Communications. 15(1), 1-15. DOI: 10.1038/s41467-024-47590-0, https://www.nature.com/articles/s41467-024-47590-0

    [ad_2]

    Source link

  • Study reveals age-specific differences in nasal cells’ response to SARS-CoV-2

    Study reveals age-specific differences in nasal cells’ response to SARS-CoV-2

    [ad_1]

    Important differences in how the nasal cells of young and elderly people respond to the SARS-CoV-2 virus, could explain why children typically experience milder COVID-19 symptoms, finds a new study led by researchers at UCL and the Wellcome Sanger Institute.

    The study, published in Nature Microbiology, focused on the early effects of SARS-CoV-2 infection on the cells first targeted by the viruses, the human nasal epithelial cells (NECs).

    These cells were donated from healthy participants from Great Ormond Street Hospital (GOSH), University College London Hospital (UCLH) and the Royal Free Hospital, including children (0-11 years), adults (30 – 50 years) and, for the first time, the elderly (over 70 years).

    The cells were then cultured using specialized techniques, allowing them to regrow into the different types of cells you originally find in the nose. Using single-cell RNA sequencing techniques that enable scientists to identify the unique genetic networks and functions of thousands of individual cells, the team identified 24 distinct epithelial cell types. Cultures from each age group were then either mock infected or infected with SARS-CoV-2.

    The researchers found that, after three days, the NECs of children responded quickly to SARS-CoV-2 by increasing interferon (the body’s first line of anti-viral defense) – restricting viral replication. However, this early anti-viral effect became less pronounced with age.

    The researchers also found that NECs from elderly individuals not only produced more infectious virus particles, but also experienced increased cell shedding and damage.

    The strong antiviral response in the NECs of children could explain why younger people typically experience milder symptoms. In contrast, the increased damage and higher viral replication found in NECs from elderly individuals could be linked to the greater severity of disease observed in older adults.

    Project lead, Dr Claire Smith (Associate Professor at UCL Great Ormond Street Institute of Child Health), said: “Our research reveals how the type of cells we have in our nose changes with age, and how this affects our ability to combat SARS-CoV-2 infection. This could be crucial in developing effective anti-viral treatments tailored to different age groups, especially for the elderly who are at higher risk of severe COVID-19.”

    By carrying out SARS-CoV-2 infections of epithelial cells in vitro and studying the responses with single cell sequencing, we get a much more detailed understanding of the viral infection kinetics and see big differences in the innate immune response between cell types.”


    Dr Kerstin Meyer, Co-Senior Author, Wellcome Sanger Institute

    Children infected with SARS-CoV-2 rarely progress to respiratory failure, but the risk of mortality in infected people over the age of 85 remains high, despite vaccination and improving treatment options.

    The research underscores the importance of considering age as a critical factor in both research and treatment of infectious diseases.

    Co-senior author, Dr Marko Nikolic (UCL Division of Medicine), said: “It is fascinating that when we take away immune cells from nasal samples, and are only left with nasal epithelial cells grown in a dish, we are still able to identify age-specific differences in our body’s response to the SARS-CoV-2 between the young and elderly to explain why children are generally protected from severe COVID-19.”

    Dr Smith added: “Understanding the cellular differences at the initiation of infection is just the beginning. We now hope to investigate the long-term implications of these cellular changes and test therapeutic interventions using our unique cell culture model. This ‘gold-standard’ system is only possible with the support of our funders and the willingness of participants to provide their samples.”

    The team suggest that future research should consider how aging impacts the body’s response to other viral infections.

    This study was funded by UK Research and Innovation (UKRI), and the National Institute for Health and Care Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre, Wellcome and the Chan Zuckerberg Foundation.

    Source:

    Journal reference:

    Woodall, M. N. J., et al. (2024). Age-specific nasal epithelial responses to SARS-CoV-2 infection. Nature Microbiology. doi.org/10.1038/s41564-024-01658-1.

    [ad_2]

    Source link

  • Vosoritide’s first phase 2 study shows increased growth in children with hypochondroplasia

    Vosoritide’s first phase 2 study shows increased growth in children with hypochondroplasia

    [ad_1]

    Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital.

    This is the first medicine that has been developed to specifically target the pathway involved in hypochondroplasia. These findings will help inform future studies of vosoritide for addressing growth disorders.” 

    Andrew Dauber, M.D., Chief of Endocrinology at Children’s National

    This clinical trial funded by BioMarin is the first-of-its-kind to treat children with genetic short stature who do not have achondroplasia. 

    The team found the annualized growth velocity increased by 2.26 standard deviation (SD) and the height standard deviation score (SDS) increased by 0.36 SD during the treatment period versus the observation period. Hypochondroplasia specific height SDS increased by 0.38 SD, according to the trial published in eClinicalMedicine

    The authors studied 24 children with hypochondroplasia. Half were female and 22 out of 24 had the p.Asn540Lys variant in the fibroblast growth factor receptor 3 (FGFR3) gene. The mean age was 5.86 years old, and the baseline height was between -4.78 SD to -2.27 SD. The trial consisted of a 6-month observation period to establish a baseline annualized growth velocity followed by a 12-month intervention period during which vosoritide was administered daily via subcutaneous injection at a dose of 15 micrograms/kg/day.

    The researchers found the absolute annualized growth velocity increased from a mean of 5.12 +/- 1.36 cm/year during the observation period to 6.93 +/- 0.93 cm/year during the intervention period for a mean difference of 1.81 cm/year for children with this condition. During the trial, the researchers also noted there were no treatment-related serious adverse events and no one discontinued therapy.

    The study findings also showed standing height SDS increased by 0.37 SD during the year of treatment or 0.41 SD using hypochondroplasia specific growth charts.

    Other growth-related conditions included in this phase 2 trial were Noonan syndrome, Neurofibromatosis type 1, Costello syndrome, NPR2 mutations and Aggrecan mutations. This manuscript includes only information specific to hypochondroplasia. Full data for all conditions studied in the trial will be available at a later date. 

    “Patients have come from all over the world to be part of our trial,” Dr. Dauber says. “We’re excited to see how well tolerated the medication was and how some patients had excellent responses.”

    Source:

    Journal reference:

    Dauber, A., et al. (2024). Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. eClinicalMedicine. doi.org/10.1016/j.eclinm.2024.102591.

    [ad_2]

    Source link

  • PET/MRI combination reduces unnecessary prostate biopsies, study shows

    PET/MRI combination reduces unnecessary prostate biopsies, study shows

    [ad_1]

    PET/MRI can improve diagnostic accuracy for prostate cancer patients and help avoid unnecessary biopsies, according to new research published in the April issue of The Journal of Nuclear Medicine. By applying the PRIMARY scoring system to PET/MRI results, researchers found that more than 80 percent of unnecessary biopsies could be avoided at the expense of missing one in eight clinically significant prostate cancer cases.

    The Prostate Imaging Reporting and Data System (PI-RADS) is a five-point scale used to evaluate suspected prostate cancer on MR images. PI-RADS category 3, which presents an unclear suggestion of clinically significant prostate cancer, remains a diagnostic challenge. Although biopsy is recommended under the current guidelines, less than 20 percent of PI-RADS 3 lesions contain clinically significant prostate cancer.

    PI-RADS 3 lesions present a dilemma to both urologists and patients because immediate biopsy could be unnecessary; however, a monitoring strategy could lead to some missed diagnoses of clinically significant prostate cancer. Hence, specifically ruling out clinically significant prostate cancer among PI-RADS 3 lesions has significant clinical implications.”


    Hongqian Guo, MD, urologist at Nanjing Drum Tower Hospital at the Affiliated Hospital of Nanjing University Medical School in Nanjing, China

    In this study, 56 men with PI-RADS 3 lesions underwent 68Ga-PSMA PET/MRI. The five-level PRIMARY system, which is based on a combination of 68Ga-PSMA pattern, localization, and intensity information, was used to report prostate 68Ga-PSMA PET/MRI findings. After imaging, all patients underwent prostate systematic biopsy in combination with targeted biopsy to determine clinically significant prostate cancer.

    Among the 56 patients, clinically significant prostate cancer was detected in eight patients (14.3 percent) by biopsy. When a PRIMARY score of at least four was used to make a biopsy decision in men with PI-RADS 3 lesions, 40 of 48 (83.3 percent) participants could have avoided unnecessary biopsies, at the expense of missing 1 in 8 (12.5 percent) of clinically significant prostate cancer cases.

    “By demonstrating the additive value of 68Ga-PSMA PET/MRI in classifying PI-RADS 3 lesions, this study provides new insight into the clinical indication for 68Ga-PSMA PET/MRI,” noted Guo. “In the future, PI-RADS 3 patients could be referred for 68Ga-PSMA PET/MRI before prostate biopsy.”

    This study was published online in March 2024.

    Source:

    Journal reference:

    Shi, J., et al. (2024). The Value of68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study. The Journal of Nuclear Medicine. doi.org/10.2967/jnumed.123.266742.

    [ad_2]

    Source link

  • Study reveals metabolic markers linked to long COVID-19 severity

    Study reveals metabolic markers linked to long COVID-19 severity

    [ad_1]

    Long COVID-19, or post-acute sequelae of SARS-CoV-2 infection (PASC), is a global health phenomenon characterized by persistent symptoms following the acute phase of COVID-19. Affecting millions worldwide, it leads to sustained healthcare needs and impacts workforce participation due to symptoms such as fatigue and cognitive impairments. The condition highlights the necessity for ongoing research, healthcare system adjustments, and the formulation of targeted treatments to address its prolonged effects on individuals and economies.

    A recently published study in Clinics Journal (Elsevier) has shed light on significant metabolic changes in non-vaccinated individuals with Long COVID-19, offering key insights into disease severity. This study was led by Marvin Edeas, MD, PhD, Université de Paris, Institut Cochin, INSERM 1016, France, and a team of international researchers led by Jumana Saleh, PhD, Sultan Qaboos University Hospital, Oman.

    Published under the title “Reduced HDL-cholesterol in Long COVID-19: A Key Metabolic Risk Factor Tied to Disease Severity”, the study examined 88 patients across varying degrees of initial disease severity (mild, moderate, and severe) compared to a control group comprising 29 healthy individuals.

    Findings from the controlled study revealed major metabolic shifts, particularly a substantial reduction in HDL-cholesterol (HDL-C) levels, coupled with a twofold increase in ferritin levels and insulin resistance among severe Long COVID-19 cases, compared to milder cases and the control group. These metabolic markers emerged as leading predictors of disease severity, offering novel understandings of Long COVID-19 management and treatment.

    Our research has, for the first time, established a direct correlation between HDL-C and ferritin levels and the severity of Long COVID-19. The decline in HDL-C levels and the rise in ferritin levels observed in patients, influenced by the severity of the initial infection, could potentially play a role in the persistence and progression of Long COVID-19 symptoms”.

    Marvin Edeas, MD, PhD, Université de Paris, Institut Cochin, INSERM 1016, France

    This study is critical in understanding Long COVID-19 and its long-term impacts on metabolic health.

     The research findings suggest that HDL-C and ferritin levels could serve as crucial markers and therapeutic targets, opening new avenues for treatment strategies aimed at mitigating the long-term effects of the disease. By considering these metabolic markers, we can shape preventive strategies and significantly mitigate the long-term impacts of COVID-19 on patients’ health.

    The function of HDL-C in immune response modulation

    The observed correlation between diminished levels of HDL-cholesterol (HDL-C), the severity of COVID-19, and its prolonged course might be explained by HDL-C’s function as a modulator of the immune response. This includes its roles as an anti-inflammatory, antioxidant, and antiatherogenic agent, particularly vital during the heightened inflammatory response triggered by the virus. Investigating HDL-C’s utility beyond its conventional role in cholesterol transport is crucial for a comprehensive understanding of COVID-19 and its secondary health effects, such as long-COVID.

    Implications of lipid remodeling during SARS-CoV-2 infection

    Extensive research indicates that COVID-19 precipitates notable shifts in the host’s lipid metabolism, leading to the accumulation of cellular lipid reserves. These alterations aid in the viral takeover of host cellular mechanisms, thus facilitating the progression of the infection. This theory gains support from laboratory evidence showing the cessation of viral replication upon the administration of small molecule lipid inhibitors, highlighting the critical dependence of the virus on host lipid resources for replication.

    The interrelation of iron dysregulation, HDL-C, and ferroptosis in COVID-19

    A notable aspect of the interplay between HDL-C functionality and iron homeostasis is the process of ferroptosis, induced by lipid peroxidation and disturbed iron balance, characterized by the buildup of iron and products of lipid oxidation. This leads to diminished antioxidant defense capabilities. HDL-C is influential in mitigating the detrimental effects associated with ferroptosis, underscoring the significance of maintaining balanced iron levels in COVID-19 management.

    “Our findings highlight the exacerbating effect of impaired iron regulation on COVID-19 progression, further complicated by the disrupted protective functions of HDL-C”, stated Jumana Saleh.

    The dynamic competition between host metabolic processes and viral interference

    The outcome of the “war”, between the host’s metabolic defenses and viral invasion strategies, axes on the control over iron and lipid resources. The virus strategically targets these metabolic reserves to support its replication and spread. For Marvin Edeas, this battle underscores the complex interaction between host metabolic pathways and viral mechanisms, emphasizing the strategic importance of iron and lipid regulation in determining the course and outcome of COVID-19 infection.

    How does the strategic alteration of iron and HDL-C levels by a virus contribute to its underlying aim of targeting mitochondria to disrupt host defense mechanisms? Marvin Edeas, founder of World Mitochondria Society, commented on the perspective of this study.

    “In the intricate dance of viral infection, the virus employs a calculated strategy aimed directly at the heart of the host’s cellular energy and defense systems -; the mitochondria. By subtly manipulating and altering the host’s iron metabolism and HDL-C levels, the virus orchestrates a multifaceted attack designed to undermine mitochondrial integrity and function. This strategic disruption serves to weaken the mitochondria, a crucial step in the virus’s broader aim to compromise the host’s ability to mount an effective defense. Through this sophisticated mechanism of action, the virus ensures its survival and proliferation within the host, highlighting the importance of understanding these viral tactics for the development of targeted therapeutic interventions”.

    The implications of this study are broad, providing a new understanding of Long COVID-19’s impact on metabolic health and laying the foundation for future research and therapeutic interventions aimed at improving patient outcomes.

    Source:

    Journal reference:

    Al-Zadjali, J., et al. (2024). Reduced HDL-cholesterol in long COVID-19: A key metabolic risk factor tied to disease severity. Clinics. doi.org/10.1016/j.clinsp.2024.100344.

    [ad_2]

    Source link

  • Non-invasive imaging test identifies patients needing heart procedures

    Non-invasive imaging test identifies patients needing heart procedures

    [ad_1]

    A new study showed that a non-invasive imaging test can help identify patients with coronary artery blockage or narrowing who need a revascularization procedure. The findings were published as a Special Report in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

    Doctors use coronary CT angiography (CTA) to diagnose narrowed or blocked arteries in the heart. A CTA exam receives a score from mild (0-1) to moderate (2-3) to severe (4-5). Patients with scores above 3 typically require medical treatments and can potentially benefit from stents or surgeries (revascularization) to restore blood flow to the heart.

    CTA tells you the degree to which a vessel is blocked. But the degree of blockage doesn’t always reliably predict the amount of blood flow in the vessel.”


    Mangun Kaur Randhawa, M.D., post-doctoral research fellow, Department of Radiology at Massachusetts General Hospital (MGH), Boston

    Doctors have traditionally relied on an invasive procedure known as invasive coronary angiography to image vessels and more recently have added other invasive tests like fractional flow reserve (FFR) to identify and assess significant blockages in the vessels. CT-FFR is a relatively new alternative that non-invasively models a patient’s coronary blood flow using CTA images of the heart, AI algorithms and/or computational fluid dynamics.

    To assess the impact of the selective use of CT-FFR on clinical outcomes, Dr. Randhawa’s research team conducted a retrospective study of patients who underwent coronary CTA at MGH between August 2020 and August 2021.

    During the study period, 3,098 patients underwent coronary CTA. Of these, 113 coronary bypass grafting patients were excluded. Of the remaining 2,985 patients, 292 (9.7%) were referred for CT-FFR analysis, and eight of these exams were excluded, leaving a final study group of 284.

    As expected, most referrals to CT-FFR were patients with scores of 3 or above. CT-FFR was requested in the majority (73.5 %) of patients with a score of 3 (moderate narrowing/blockage).

    “In patients with moderate narrowing or blockage of the arteries, there can be ambiguity about who would benefit from invasive testing and revascularization procedures,” Dr. Randhawa said. “CT-FFR helps us identify and select those patients who are most likely to benefit.”

    Out of the 284 patients, 160 (56.3%) had a negative CT-FFR result of > 0.80, 88 patients (30.9%) had a clearly positive (abnormal) result of ≤ 0.75, and the remaining 36 patients (12.6%) had a borderline result between 0.76-0.80.

    Patients with significant narrowing/blockages on coronary CTA who underwent CT-FFR had lower rates of invasive coronary angiography (25.5% vs. 74.5%) and subsequent percutaneous coronary intervention (21.1% vs. 78.9%) than patients who were not referred for a CT-FFR.

    “CT-FFR helps us identify patients who would most benefit from undergoing invasive procedures and to defer stenting or surgical treatment in patients who likely won’t,” said senior author Brian B. Ghoshhajra, M.D., M.B.A., associate chair for operations and academic chief of cardiovascular imaging at MGH. “CT-FFR makes the CT ‘better’, but we found that the benefits were highest when used selectively.”

    Dr. Ghoshhajra added that their CT-FFR analysis was successful in the large majority of patients, regardless of challenging factors such as elevated or irregular heart rates and obesity.

    “When you objectively measure coronary artery flow with CT-FFR, you induce fewer patients to be further investigated and treated, because you tend to treat not just what the eyeball sees, but what the physiology supports,” he said.

    The researchers said the study results demonstrate the utility of CT-FFR in clinical practice, when used selectively, highlighting its potential to reduce the frequency of invasive procedures in patients with significant coronary artery narrowing or blockages without compromising safety.

    Source:

    Journal reference:

    Randhawa, M. K., et al. (2024). Selective Use of CT Fractional Flow at a Large Academic Medical Center: Insights from Clinical Implementation after 1 Year of Practice. Radiology. Cardiothoracic Imaging. doi.org/10.1148/ryct.230073.

    [ad_2]

    Source link

  • AI model can accurately screen for post-traumatic stress disorder after childbirth

    AI model can accurately screen for post-traumatic stress disorder after childbirth

    [ad_1]

    A generative artificial intelligence (AI) model that can analyze the narrative accounts of women who have undergone recent childbirth has shown the ability to accurately screen for post-traumatic stress disorder (CB-PTSD), a study by Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system has found.

    By exploring the capabilities and shortcomings of several models from OpenAI, including ChatGPT, the researchers identified a version that offers rich insights into maternal mental health following traumatic childbirth.

    The model can fit seamlessly into routine obstetric care and could potentially be harnessed to assess other mental health disorders. The results of the study were published in Scientific Reports.

    Evaluation of PTSD related to traumatic birth currently relies on extensive clinician evaluation, which fails to meet the urgent need for a rapid, low-cost assessment strategy.”


    Sharon Dekel, PhD, director of MGH’s Postpartum Traumatic Stress Disorders Research Program, and senior author of the study

    “The use of brief patient narratives of childbirth analyzed by AI’s text-based computational methods could become an efficient, low-cost, and patient-friendly strategy for detecting CB-PTSD after a traumatic birth and with more research this tool may potentially aid in identifying women at risk for CB-PTSD before the condition fully develops.”

    For an estimated eight million women a year globally, childbirth that is traumatic and/or medically complicated is expected to trigger post-traumatic stress disorder, a condition historically has been associated with military combat or severe sexual assault.

    In recent years, childbirth has become acknowledged as a significant PTSD trigger which, if left untreated, can impair the health of both the mother and child and result in significant societal costs.

    In previous studies, Dekel’s lab found evidence that brief psychological interventions delivered soon after traumatic childbirth can reduce maternal childbirth-related PTSD symptoms.

    In their latest study, Dekel in collaboration with first author Alon Bartal, PhD, of Bar-Ilan University in Israel, investigated the effectiveness of artificial intelligence and related machine learning (ML) analysis strategies to detect CB-PTSD.

    Specifically, they evaluated the performance of different large language models (LLMs) and variations of ChatGPT and their ability to extract novel insights from text-based data sets derived from the brief narrative descriptions by postpartum women of their childbirth experience.

    As part of their work, the team collected short narrative accounts from 1,295 women who had recently given birth.

    The study focused on an OpenAI model known as text-embeddings-ada-002, which converted narrative data from the personal accounts of women with and without probable CB-PTSD to a numerical format that was then analyzed by a trained machine learning algorithm developed by the team.

    Researchers showed this model had superior performance in identifying postpartum traumatic stress compared to other ChatGPT and large language models, which are typically trained on huge volumes of data allowing them to understand, analyze and interpret natural language.

    “The reliance of the ML model using childbirth narrative input from the Open AI model as its exclusive data source presents an efficient mechanism for data collection during the vulnerable postpartum period, demonstrating 85 percent sensitivity and 75 percent specificity in identifying CB-PTSD cases,” notes Dekel.

     “Moreover, the model we developed could potentially improve accessibility to CB-PTSD screening and diagnosis by fitting seamlessly into routine obstetric care and providing a foundation for commercial product development and mainstream adoption.”

    Dekel, whose research program is dedicated to exploring women’s mental health following traumatic childbirth, underscores the clinical benefits of using a pre-trained large language model to assess potential PTSD in new mothers.

    “Early intervention is essential to prevent the progression of this disorder to chronic stages, which can seriously complicate treatment,” the MGH investigator points out.

    “Our unique approach could introduce an innovative and cost-effective screening strategy for identifying high-risk women and facilitating timely treatment. It may also holds promise for assessing other mental health disorders, and consequently improving patient outcomes.”

    The emergence of artificial intelligence tools in health has been groundbreaking and has the potential to positively reshape the continuum of care. Mass General Brigham, as one of the nation’s top integrated academic health systems and largest innovation enterprises, is leading the way in conducting rigorous research on new and emerging technologies to inform the responsible incorporation of AI into care delivery, workforce support, and administrative processes. 

    Dekel is a psychologist at MGH, and assistant professor of Psychology at Harvard Medical School. Bartal is an assistant professor of Information Systems at Bar-Ilan University in Israel. Co-authors in the Dekel Laboratory include Kathleen Jagodnik, PhD, a Harvard research fellow, and Sabrina Chan, a clinical research coordinator.

    Dekel was supported by funds from the NIH (Eunice Kennedy Shriver National Institute of Child Health and Human Development, grants R01HD108619, R21HD109546, and R21HD100817).

    Source:

    Journal reference:

    Bartal, A., et al. (2024). AI and narrative embeddings detect PTSD following childbirth via birth stories. Scientific Reportsdoi.org/10.1038/s41598-024-54242-2.

    [ad_2]

    Source link

  • Patient-centered cardiovascular care enhances outcomes

    Patient-centered cardiovascular care enhances outcomes

    [ad_1]

    Adult cardiovascular care centered on the patient can improve individuals’ experiences and their medical outcomes, according to a new American Heart Association Scientific Statement published today in Circulation.

    Patient-centered care means seeing the patient as a person and being respectful of their beliefs, preferences and values. Patient-centered care combines the health care professional’s expertise with consideration of the patient’s health priorities. It involves empowering patients to make informed decisions by providing information and developing an active partnership among the patient, family and the health care team. Patient-centered care does not mean that patients can choose what they want, when they want.”


    Michael J. Goldfarb, M.D., M.Sc., chair of the scientific statement writing committee and associate professor of cardiology at the Jewish General Hospital and McGill University in Montreal, Quebec, Canada

    “There is a need for health care professionals managing adults with heart disease to receive guidance and practical tools on how to incorporate a person-centered care approach into routine clinical practice,” said Goldfarb.

     The new scientific statement describes several elements that are essential to patient-centered care, including shared decision-making, medication management and patient-oriented outcomes.

    Shared decision-making is a collaborative partnership among patients, family and health care professionals based on trust, mutual respect and open and honest communication. Health professionals need to consider their patient’s level of health literacy and provide clear, jargon-free and relevant information about risk factors, current health conditions and the realities, risks and benefits of possible screening and treatment options. Patients must have the opportunity to ask questions, express their values, preferences and goals, and work together with the medical team to agree on a plan for managing their heart disease.

    Although the benefits of using medication to prevent and treat heart disease are well known, for a myriad of reasons, more than half of patients with cardiovascular disease do not always take their medications as prescribed. Conditions such as high blood pressure and high cholesterol raise the risk of heart attack and stroke, but undertreatment of these silent conditions is common.

    Patient-centered discussions of current and proposed medications may also help to improve adherence to needed medications and minimize drug costs and side effects. In some cases, a combination pill may reduce the number of tablets that must be taken each day, or a less expensive but equally effective medication may be substituted for a more expensive option. An open, honest discussion about medication may also lead to the decision to eliminate a longstanding medication that may no longer be needed.

    “Prior to starting, adjusting or stopping cardiovascular medications, there is a need to establish and take into account patient preferences and goals,” said Goldfarb.

    While physical examinations and lab tests provide important data about how a patient with heart disease is doing, patient-centered care incorporates people’s own reports of their physical functioning, symptom burden, emotional well-being, social functioning and quality of life. Collecting this information gives health care professionals a more complete picture of how a patient is doing so they may detect subtle changes in the progression of heart disease and assess the impact (negative or positive) of current or proposed treatments.

    “While some care outcomes are important for health care professionals and health systems, these may not always reflect what is important to the patient. For example, while the length of a hospital stay is often recorded as a marker of care quality, the patient may prioritize their physical functioning and quality of life after a heart attack,” said Goldfarb.

    Ensuring patient-centered care for all

    The statement gives special consideration to overcoming barriers to patient-centered care and in applying patient-centered care to the people who carry an outsized burden of cardiovascular disease. For example:

    • People from underrepresented and historically underserved races and ethnicities have the highest rates of cardiovascular disease and death and are often affected by adverse social determinants of health (SDOH, including measures such as economic stability, education, neighborhood safety and access to quality health care ). Effective patient-centered care may involve the use of tools to assess SDOH, followed by care provided by culturally and linguistically competent multidisciplinary teams that include social workers, interpreters and patient navigators.
    • Older adults often face other complex aging-related health issues in addition to heart disease. Patient-centered care needs to consider age-associated risks (such as multiple medications, frailty, dementia, falls, social isolation) when evaluating the pros and cons of various medications and interventions.
    • Women can benefit from patient-centered cardiovascular care throughout adulthood, including care to prevent and treat pregnancy-related heart issues, and care at time of menopause.
    • Individuals with behavioral and mental health disorders may face psychological challenges that often impact heart health. Patient-centered care for these individuals should include behavioral health services in addition to specialized cardiovascular care.
    • Adults with congenital heart disease are an increasing group of patients who, throughout their lifetimes, benefit from a patient-centered approach as they transition from pediatric into adult care and face decisions about high-level medical and surgical treatment.
    • People with physical disabilities often have reduced access to health services and report worse overall health than adults without disabilities. According to the statement, the health care system should address inadequate access to preventive care and the treatment of heart disease and other chronic conditions for individuals with disabilities.

    Barriers to patient-centered care

    There are many barriers to incorporating patient-centered care, including those arising from patients, clinicians and health systems.

    • Patients, who may distrust or lack access to the health system, have limited health literacy, limited English proficiency or cultural barriers to communicating with health care professionals, be more concerned about their caregivers and family than themselves, or hold medical beliefs and preferences that conflict with best health practices.
    • Clinicians, who operate under time pressures and increasing demands for documentation, may have different incentives than patients and may also work in settings where the workforce lacks the diversity of the patients served.
    • Health systems may be fragmented, provide limited access to specialty care, have limited space or inadequate systems to share information and/or lack team-based care.

    “Patient-centered care is possible-;and already occurs to a certain extent-;in today’s care delivery systems. Further development and inclusion of patient-centered outcomes measures will be important for optimizing care for patients, their families and caregivers,” said Goldfarb.

    This scientific statement was prepared by the volunteer writing group on behalf of the American Heart Association’s Council of Clinical Cardiology; the Council on Cardiovascular and Stroke Nursing; the Council on Hypertension; the Council on Lifestyle and Cardiometabolic Health; the Council on Peripheral Vascular Disease; and the Council on Quality of Care and Outcomes Research. American Heart Association scientific statements promote greater awareness about cardiovascular diseases and stroke issues and help facilitate informed health care decisions. Scientific statements outline what is currently known about a topic and what areas need additional research. While scientific statements inform the development of guidelines, they do not make treatment recommendations. American Heart Association guidelines provide the Association’s official clinical practice recommendations.

    Source:

    Journal reference:

    Goldfarb, M. J., et al. (2024) Patient-Centered Adult Cardiovascular Care: A Scientific Statement From the American Heart Association. Circulation. doi.org/10.1161/CIR.0000000000001233.

    [ad_2]

    Source link

  • Hospital sinks fuel antibiotic-resistant bacteria spread

    Hospital sinks fuel antibiotic-resistant bacteria spread

    [ad_1]

    A new study published today in the American Journal of Infection Control (AJIC) reports the infection prevention steps taken to control a months-long multispecies outbreak of carbapenemase-producing Enterobacterales that occurred in a pediatric ward at the Toho University Omori Medical Center in Tokyo in 2017. This study highlights the particular vulnerability for contamination through sinks and other water sources; indeed, even replacing all sinks in the ward did not stop this outbreak.

    Carbapenemase-producing Enterobacterales (CPE) are a major public health threat because of their resistance to widely used antibiotics. The biological mechanism that confers multidrug resistance can be passed from one bacterial species to another, contributing to the growing epidemic of antimicrobial resistance. An outbreak of one CPE species in a hospital has the potential to turn into an outbreak involving many species, making it that much more difficult to stop. Many studies have shown that there is a high risk of CPE contamination in and around hospital sinks.

    This new report from an academic medical center in Tokyo details the detection of CPE in a single patient in June 2016, which appears to have triggered an outbreak starting in March 2017 and ending in October 2017. The outbreak involved a total of 19 pediatric patients. The infection prevention team sampled microbes from patients and the environment of the pediatric ward to better understand how the outbreak was spreading. This sampling identified nine sinks contaminated with CPE, including six in hospital rooms and three more in a nurse center, a waste room, and an ice machine. The CPE-positive sinks were all found in rooms where CPE-positive patients had been treated. In rooms with CPE-negative patients, no sink contamination was detected.

    As part of the outbreak control process, genome analysis was performed to identify the specific resistance mechanisms found in the bacterial strains, which included Klebsiella variicola, Klebsiella quasipneumoniae, and Escherichia coli, among others. Identical DNA sequences from all samples but one support the idea that the resistance mechanism could have been passed from one bacterial species to another within the hospital.

    To help rein in the outbreak, all sinks in the pediatric ward were replaced with new ones in June 2017, and the new sinks were thoroughly disinfected with hydrogen peroxide. However, CPE contamination continued even after that step. The discovery of the same bacterial species in sinks in adjoining rooms indicates that pathogen transmission may be possible from one sink to another via the drains and connected plumbing.

    Other measures implemented by the infection prevention team -; composed of doctors, nurses, pharmacists, and microbiologists -; included recommending hand disinfection after using sinks, introducing disposable tools for cleaning sinks, prohibiting mouth-washing with sink water, enacting disinfection and drying procedures to any items exposed to sink water, and more. Finally, after October 2017, no further CPE contamination was identified in patient samples or environmental surveillance.

    After months of intense infection control protocols, we were at last able to declare an end to this outbreak. Our experience highlights the importance of focusing on sinks and other water-related areas in hospital wards, as these are critical for CPE transmission and therefore major fronts in the fight against antibiotic resistance.”

    Sadako Yoshizawa, MD, PhD, Associate Professor in the Department of Microbiology and Infectious Diseases at Toho University School of Medicine, Deputy Director of Clinical Laboratory at Toho University Omori Medical Center, and corresponding author of the study

    Additional details from the study include:

    • Toho University Omori Medical Center is a 916-bed academic medical center with 55 pediatric inpatient beds.
    • The first patient to be detected with CPE in June 2016 was a one-year-old boy hospitalized with cardiac disease.
    • The resistance mechanism detected in this outbreak was a plasmid enabling the production of carbapenemase, which can make bacteria resistant to the carbapenem class of antibiotics. In this outbreak, all CPE strains except one harbored blaIMP-1, with identical blaIMP-1-carrying IncM1 plasmids.

    The tremendous effort that went into controlling this outbreak is representative of the comprehensive and holistic approach to infection prevention that is required in these situations. Even a measure as definitive as replacing contaminated sinks may not be enough to stop the spread of antibiotic-resistant organisms. This outbreak ended because the infection prevention team implemented a bundle of core processes related to hand hygiene, and the use and disinfection of hospital sinks.”


    Tania Bubb, PhD, RN, CIC, FAPIC, 2024 APIC president

    Source:

    Journal reference:

    Tsukada, M., et al. (2024) The outbreak of multispecies carbapenemase-producing Enterobacterales associated with pediatric ward sinks: IncM1 plasmids act as vehicles for cross-species transmission. American Journal of Infection Control. doi.org/10.1016/j.ajic.2024.02.013.

    [ad_2]

    Source link